Device Post-Market Work In Scope Under MHRA’s 16% Cost Coverage Fee Hike

Bad News Or Balanced And Necessary? System Users To Have Their Say

The UK MHRA has given medtech companies and stakeholders seven weeks to comment on proposed use fee rises for 2025. 16% rises are mooted for a variety of services.

Fees

Continued cost recovery is the aim of proposed medtech user fee rises by the UK Medicines and Healthcare products Regulatory Agency (MHRA). The hikes would take effect in April 2025.

A seven-week consultation closing 24 October allows stakeholders to give their views on what one regulatory specialist, commenting on social...

More from United Kingdom

More from Europe